Targets for future clinical trials in Huntington's disease: What's in the pipeline?

@inproceedings{Wild2014TargetsFF,
  title={Targets for future clinical trials in Huntington's disease: What's in the pipeline?},
  author={Edward J. Wild and Sarah J Tabrizi},
  booktitle={Movement disorders : official journal of the Movement Disorder Society},
  year={2014}
}
The known genetic cause of Huntington's disease (HD) has fueled considerable progress in understanding its pathobiology and the development of therapeutic approaches aimed at correcting specific changes linked to the causative mutation. Among the most promising is reducing expression of mutant huntingtin protein (mHTT) with RNA interference or antisense oligonucleotides; human trials are now being planned. Zinc-finger transcriptional repression is another innovative method to reduce mHTT… CONTINUE READING